In vitro antifungal activity of CAN-296: A naturally occurring complex carbohydrate

Journal of Antibiotics

Volumn 50, Issue 11, 1997, Pages 937-943

  Ben Josef, Avital Mazar ^a   Manavathu, Elias K ^a   Platt, David ^b   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IGG International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CAN 296; CARBOHYDRATE; FLUCONAZOLE; FLUCYTOSINE; KETOCONAZOLE; L 733560; PNEUMOCANDIN DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CELL WALL; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MUCOR; PRIORITY JOURNAL; YEAST;

EID: 0031464022     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.7164/antibiotics.50.937     Document Type: Article

References (12)

1. POLAK, A. & P. G. HARTMAN: Antifungal chemotherapy- are we winning? Prog. Drug Res. 37: 131-269, 1991
2. GALLIS, H. A.; H. DREW & W. W. PICKARD: Amphotericin B: 30 years of experience. Rev. Incct. Dis. 12: 308-329, 1990
3. BAILY, G. G.; F. M. PERRY, D. W. DENNING & B. K. MANDEL: Fluconazole resistance candidosis in an HIV cohort. AIDS 8: 787-792, 1994
4. KOMSHIAN, S. V.; A. UWAYDAH, J. D. SOBEL & L. R. CRANE: Fungemia caused by Candida species and Torulopsis glabrata in hospitalized patients. Frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11: 379-390, 1989
5. NOBRE, G.; E. MENDES, M. CHARRUA & O. CRUZ: Ketoconazole resistance in Torulopsis glabrata. Mycopathologia 107: 51-55, 1989
6. VAZQUEZ, J. A.; M. LYNCH & J. D. SOBEL: In vitro activity of a new pneumocandin antifungal agent, L-733,560. against azole-susceptible and resistant Candida and Torulopsis species. Antimicrob. Agents Chemother. 39: 2689-2691, 1995
7. WARNOCK, D.; J. BRUKE, N. J. COPE, E. JOHNSON, N. VON FRAUNHOFER & E. WILLIAMS: Fluconazole resistance in Candida glabrata. Lancet I: 1310, 1988
8. WINGARD, J. R.; W. G. MERZ, M. G. RINALDI, T. R. JOHNSON, J. E. KARP & R. SARAL: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 18: 1274-1277, 1991
9. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing for yeast; Tentative standard. Document M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa, 1995
10. ESPINEL-INGROFF, A.; K. DAWSON, M. PFALLER, E. ANAISSIE, B. BRESLIN, D. DIXON, A. FOTHERGILL, V. PAETZNICK, J. PETER, M. RINALDI & T. WALSH: Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicro. Agents Chemother. 39: 314-319, 1995
11. th Annual Meeting of the American Society for Microbiology, Washington, DC. Abstract C356, 1995
12. VENKATESWARLU, K.; D. W. DENNING, N. J. MANNING & S. L. KELLY: Comparion of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob. Agents Chemother. 40: 1382-1386, 1996